L-Ornithine Dosage for Adults
For hepatic encephalopathy in liver cirrhosis, use intravenous L-ornithine-L-aspartate (LOLA) at 30 g/day, which is the established guideline-recommended dose that improves clinical outcomes. 1
Clinical Context and Route-Specific Dosing
The dosing of L-ornithine depends critically on the clinical indication and route of administration:
For Hepatic Encephalopathy (Primary Medical Use)
Intravenous LOLA: 30 g/day is the standard dose recommended by the 2020 Korean Association for the Study of the Liver (KASL) guidelines 1
- This dose demonstrated superior outcomes when combined with lactulose versus lactulose alone
- Patients showed faster symptom recovery (1.92 vs 2.50 days, p=0.002) 1
- More effective reduction in hepatic encephalopathy grade within 1-4 days (OR 2.06-3.04) 1
- Most effective for West-Haven criteria grade 1-2 hepatic encephalopathy 1
Oral LOLA dosing for hepatic encephalopathy remains less well-established, with guidelines noting that "further studies are required to assess its efficacy in managing overt hepatic encephalopathy" 1
The 2023 Critical Care Medicine guidelines for acute liver failure also recommend LOLA for acute-on-chronic liver failure patients with overt hepatic encephalopathy, though they acknowledge very low quality of evidence 2.
For General Supplementation (Non-Medical Use)
For L-ornithine used as a dietary supplement outside of liver disease:
Research doses range from 400 mg/day to 14,025 mg/day (as L-ornithine hydrochloride) 3
Common effective doses in studies:
FDA-labeled product dosing: 10 drops orally, 3 times daily (specific mg amount not provided in label) 6
Important Clinical Considerations
Route matters significantly: The robust clinical evidence supporting 30 g/day applies specifically to intravenous LOLA for hepatic encephalopathy. This is not interchangeable with oral supplementation doses.
Safety profile: The systematic review of 22 clinical trials found the main adverse events were gastrointestinal disorders, with no significant difference in risk between L-ornithine supplementation and placebo (risk difference 0.00,95% CI ±0.02) 3. Maximum safe duration studied was 156 days 3.
Mechanism justifies dosing: LOLA works by providing substrates for ammonia detoxification through the urea cycle (ornithine activates carbamoyl phosphate synthetase 1) and glutamine synthesis (aspartate stimulates arginase) 1, 7. The 30 g/day IV dose achieves therapeutic ammonia reduction that lower doses may not accomplish.
Avoid common pitfalls: Do not use oral L-ornithine supplementation doses (400-2,000 mg) when treating hepatic encephalopathy—this represents a 15-75 fold underdosing compared to the evidence-based IV regimen. Conversely, do not use 30 g/day dosing for general wellness supplementation, as this exceeds studied safety parameters for non-medical use.